LV10054B - Antiviral or antibacterial compound and method of use - Google Patents

Antiviral or antibacterial compound and method of use Download PDF

Info

Publication number
LV10054B
LV10054B LVP-92-508A LV920508A LV10054B LV 10054 B LV10054 B LV 10054B LV 920508 A LV920508 A LV 920508A LV 10054 B LV10054 B LV 10054B
Authority
LV
Latvia
Prior art keywords
dimer
lysozyme
vas
ribonuclease
treatment
Prior art date
Application number
LVP-92-508A
Other languages
English (en)
Other versions
LV10054A (lv
Inventor
Witold Kiczka
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of LV10054A publication Critical patent/LV10054A/lv
Publication of LV10054B publication Critical patent/LV10054B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Claims (9)

  1. L V 10054 PRETVĪRUSU VAI ANTIBARTERIĀLS SAVIENOJUMS 5 UN TĀ LIETOŠANAS METODE PATENTA FORMULA 1. Savienojums vīrusu vai bakteriālu infekciju ārstēšanai cilvēkiem vai 10 dzīvniekiem, kurš satur no 0,001 līdz 20,0 mg - labāk apmēram no 0,1 līdz apmēram 5,0 mg - lizocīma dimēra un/vai ribonukleāzes dimēra uz ml farmaceitiski pieņemama nesēja, kurš izvēlēts no grupas, ietverošas fizioloģisku sāļa šķīdumu un ziedes bāzi, pie kam labāk, ja pēdējā satur ūdeni, parafīnu un propilēnglikolu. 15
  2. 2. Savienojums, saskaņā ar 1. punktu, kurā farmaceitiski pieņemamais nesējs ir fizioloģisks sāļa šķīdums, vislabāk 0,5 -1,5 % sāļa ūdens šķīdums, dimēra saturs tajā speciāli ir apmēram 4 mg/ml un tas domāts perorālai, vietējai un/vai intravenozai lietošanai. 20
  3. 3. Savienojums, saskaņā ar 2. punktu, kurš satur apmēram 0,8 mg lizocīma dimēra uz ml fizioloģiska sāļa šķīduma un domāts otīta ārstēšanai kā pilināms līdzeklis.
  4. 4. Savienojums, saskaņā ar 1. punktu, kurā farmaceitiski pieņemamais nesējs ir ziede, kas satur apmēram 4 mg dimēra(u) uz - apmēram 35 mg vismaz viena savienojuma no grupas, kurā ietilpst parafīns un acetilstearoiloksispirts, - apmēram 10 mg propilēnglikola un 30 - 200 ml ūdens.
  5. 5. Savienojums, saskaņā ar 2. vai 4. punktu, kurš domāts herpes vīrusu infekcijas ārstēšanai, īpaši vismaz kādas no grupas, kurā ietilpst herpes simplex, herpes zoster un herpes genitalis infekcijas. 35 2
  6. 6. Savienojums, saskaņā ar 2. vai 4. punktu, kurš satur no apmēram 4,0 līdz apmēram 20,0 mg dimēra(u) uz ml ziedes un domāts brūču un/vai maksts infekciju ārstēšanai. 5
  7. 7. Savienojums, saskaņā ar 1, punktu, kurš tiek lietots svecītes formā, satur labāk apmēram 5 mg dimēra(u) uz ml farmaceitiski pieņemamas svecītes bāzes un domāts maksts infekciju ārstēšanai.
  8. 8. Savienojums, saskaņā ar jebkuru no iepriekšējiem punktiem, kurš domāts bakteriālu vai vīrusu infekciju izcelsmes mastīta un/vai ādas slimību ārstēšanai.
  9. 9. Savienojums, saskaņā ar jebkuru no iepriekšējiem punktiem, kurš 15 domāts suņu parvovīrusa ārstēšanai.
LVP-92-508A 1988-05-26 1992-12-28 Antiviral or antibacterial compound and method of use LV10054B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17858888A 1988-05-26 1988-05-26
PCT/US1988/001785 WO1989011294A1 (en) 1988-05-26 1988-05-26 Antiviral or antibacterial compound and method of use
OA59731A OA09785A (en) 1988-05-26 1990-01-26 Antiviral or antibacterial compound and method of use

Publications (2)

Publication Number Publication Date
LV10054A LV10054A (lv) 1994-05-10
LV10054B true LV10054B (en) 1995-02-20

Family

ID=33162813

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-508A LV10054B (en) 1988-05-26 1992-12-28 Antiviral or antibacterial compound and method of use

Country Status (23)

Country Link
US (3) US5200182A (lv)
EP (1) EP0380484B1 (lv)
JP (1) JPH0649659B2 (lv)
AT (1) ATE93143T1 (lv)
AU (1) AU624331B2 (lv)
BG (1) BG60544B1 (lv)
CA (1) CA1335425C (lv)
CS (1) CS277030B6 (lv)
DK (1) DK173078B1 (lv)
ES (1) ES2011577A6 (lv)
FI (1) FI900412A0 (lv)
HK (1) HK42394A (lv)
HU (1) HU204710B (lv)
IL (1) IL90092A (lv)
LV (1) LV10054B (lv)
MA (1) MA21560A1 (lv)
MW (1) MW390A1 (lv)
OA (1) OA09785A (lv)
PH (1) PH26284A (lv)
RU (1) RU2092183C1 (lv)
WO (1) WO1989011294A1 (lv)
YU (1) YU109289A (lv)
ZA (1) ZA893382B (lv)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624331B2 (en) * 1988-05-26 1992-06-11 Nika Health Products Ltd. A composition having as its active ingredient lysozyme or ribonuclease dimer in a pharmaceutically acceptable carrier
JP2732515B2 (ja) * 1990-01-08 1998-03-30 ニカ ヘルス プロダクツ リミテッド リボヌクレアーゼ二量体の製造方法
US5989880A (en) 1990-01-08 1999-11-23 Nika Health Products Ltd. Method of preparing lysozyme dimers
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
CH682541A5 (de) * 1992-06-23 1993-10-15 Urs Viktor Dr Wirth Biochemische Inaktivierung von RNA-Viren.
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
GB2304048A (en) * 1995-08-12 1997-03-12 John William Carson Medicament containing saliva extract
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
JP2002187853A (ja) * 2000-12-21 2002-07-05 Shinei Ferumentekku:Kk 動物の乳頭除菌剤および菌環境改善方法
DE10210285A1 (de) * 2002-03-08 2003-11-13 Medigene Ag Reversibles Toxin und seine Verwendung
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US7348301B2 (en) * 2006-02-16 2008-03-25 Buckman Laboratories International, Inc. Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
EP2049151A4 (en) 2006-07-17 2010-03-24 Quintessence Biosciences Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2008109401A2 (en) * 2007-03-02 2008-09-12 Saint Simeon Lda Composition and method for treating papilloma virus and equine sarcoids
US20100317677A1 (en) * 2007-09-11 2010-12-16 Hassel Bret A Methods of Treating a Microbial Infection by Modulating RNase-L Expression and/or Activity
JP2010540681A (ja) * 2007-10-08 2010-12-24 クインテッセンス バイオサイエンシズ，インコーポレーテッド リボヌクレアーゼに基づく治療のための組成物及び方法
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
WO2010099182A1 (en) * 2009-02-25 2010-09-02 Board Of Regents Of The University Of Nebraska Activated creatinine and precursors as antibacterial agents, compositions and products containing such agents and uses thereof
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
EP2457576B1 (en) 2010-11-29 2020-07-08 Eurochit Danuta Kruszewska Lactobacillus reuteri strain for use in the medical and veterinary prophylaxis and treatment of metabolic syndrome or infections
RU2548803C2 (ru) * 2011-11-28 2015-04-20 Общество с ограниченной ответственностью " Фарматренд" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ ИНФЕКЦИЙ P. Aeruginosa, СОДЕРЖАЩАЯ РЕКОМБИНАНТНЫЙ ЛИЗОЦИМ
RU2509801C2 (ru) * 2012-03-22 2014-03-20 Борис Михайлович Куриненко СПОСОБ ИСПОЛЬЗОВАНИЯ РИБОНУКЛЕАЗЫ Bacillus intermedius
EP2674162A1 (en) 2012-05-29 2013-12-18 Danuta Kruszewska Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
US20160032413A1 (en) 2012-05-29 2016-02-04 Danuta KRUSZEWSKA Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
RU2504397C1 (ru) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
WO2014152678A1 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
US20170049863A1 (en) * 2014-02-21 2017-02-23 National University Corporation Tokyo University Of Marine Science And Technology Norovirus deactivator and method for producing same, method for deactivating norovirus, method for producing lysozyme component for norovirus deactivation use, prophylactic or therapeutic agent for norovirus infection, and external preparation for skin for norovirus deactivation purposes
WO2016017784A1 (ja) * 2014-07-31 2016-02-04 キユーピー株式会社 含水流動状組成物及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法
EP3194425A1 (en) 2014-09-17 2017-07-26 Spogen Biotech Inc. Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
LV15071B (lv) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Kompozīcija subklīniska mastīta ārstēšanai govīm
RU2634264C1 (ru) * 2016-09-19 2017-10-24 Александр Ливиевич Ураков Крем-молочко для лечения опоясывающего лишая
WO2018123821A1 (ja) 2016-12-28 2018-07-05 Dic株式会社 分散体及びそれを用いたインクジェット用インク組成物、光変換層、及び液晶表示素子
NZ763625A (en) 2017-09-20 2024-07-26 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and exosporium fragments for plant health
US20220273733A1 (en) * 2019-07-26 2022-09-01 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1268M (fr) * 1961-06-29 1962-04-24 Puiseux Médicament antimitotique et antiviral.
FR4020M (lv) * 1965-01-29 1966-03-21
DE1517751C3 (de) * 1965-07-08 1975-02-27 Eisai Co., Ltd., Tokio Verfahren zum Verhindern der Bildung von flockigen Lysozym- und/oder Lysozymsalzniederschlägen in wässrigen Lösungen, die Lysozym und/oder Lysozymsalze enthalten
DE1545644A1 (de) * 1965-12-06 1969-08-07 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen quaternaeren Scopolammoniumsalzen
GB1110504A (en) * 1966-03-18 1968-04-18 Prodotti Antibiotici Spa Pharmaceutical compositions
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
EP0187705A3 (en) * 1985-01-08 1988-05-11 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
AU624331B2 (en) * 1988-05-26 1992-06-11 Nika Health Products Ltd. A composition having as its active ingredient lysozyme or ribonuclease dimer in a pharmaceutically acceptable carrier

Also Published As

Publication number Publication date
JPH0649659B2 (ja) 1994-06-29
DK173078B1 (da) 1999-12-20
ES2011577A6 (es) 1990-01-16
MW390A1 (en) 1990-11-14
AU624331B2 (en) 1992-06-11
PH26284A (en) 1992-04-10
YU109289A (en) 1991-08-31
ZA893382B (en) 1991-01-30
HUT54060A (en) 1991-01-28
HU204710B (en) 1992-02-28
BG91270A (bg) 1993-12-24
BG60544B1 (en) 1995-08-28
JPH03504121A (ja) 1991-09-12
CS318089A3 (en) 1992-05-13
HK42394A (en) 1994-05-13
US6099835A (en) 2000-08-08
IL90092A (en) 1995-03-30
CS277030B6 (en) 1992-11-18
WO1989011294A1 (en) 1989-11-30
EP0380484B1 (en) 1993-08-18
EP0380484A1 (en) 1990-08-08
CA1335425C (en) 1995-05-02
FI900412A0 (fi) 1990-01-25
DK16890A (da) 1990-01-22
ATE93143T1 (de) 1993-09-15
DK16890D0 (da) 1990-01-22
US5466449A (en) 1995-11-14
OA09785A (en) 1994-04-15
AU1940888A (en) 1989-12-12
MA21560A1 (fr) 1989-12-31
HU883981D0 (en) 1990-12-28
US5200182A (en) 1993-04-06
LV10054A (lv) 1994-05-10
RU2092183C1 (ru) 1997-10-10

Similar Documents

Publication Publication Date Title
US6099835A (en) Method of using antiviral composition
EP0090837A1 (en) Method and composition for treating a patient suffering from interferonsusceptible disorder
CN109985069B (zh) 益生菌组合物及其用途
Al-Nakib et al. Intranasal chalcone, Ro 09–0410, as prophylaxis against rhinovirus infection in human volunteers
US6132715A (en) Method of inhibiting biosynthesis of tumor necrosis factor
US5342612A (en) Compositions for the treatment of mammalian diseases
US3721733A (en) Anti-microbial compositions containing histaminase
Grimble et al. Non-specific urethritis and the tetracyclines.
KR930004599B1 (ko) 항바이러스성 또는 항균성 조성물
Ochs Treatment of external otitis; a simple and effective technic
Cox Cefazolin therapy of urinary tract infections
DE3883392T2 (de) Verwendung eines Lysozymdimeren und/oder Ribonucleasedimeren zur Herstellung eines antiviralen oder antibakteriellen Arzneimittels.
RO110037B1 (ro) Compoziții antivirale sau antibacteriene și metodă de tratare a infecțiilor, cu acestea
JOHNSON Dermatologic evaluation of yeast, tyrothricin, chlorophyll and nitrofurazone
Feo et al. Evaluation of tritheon (aminitrozole) in male trichomoniasis
MXPA97001730A (es) Vacuna enteral para infecciones vaginales
MXPA98009256A (en) Antimicrobial treatment for herpes simplex virus and other infectious diseases